Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal

NCT03223012 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03223012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03223012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
November 15, 2017
Completion date
February 28, 2019
Enrollment
116 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis (as), crohn's disease, non-radiographic axial spondyloarthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis (ra), ulcerative colitis (uc)